SOLICITATION NOTICE
H -- Estrogen Receptor Methalation Status and Breast Cancer Risk
- Notice Date
- 8/30/2006
- Notice Type
- Solicitation Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- Reference-Number-NCI-60171-NV
- Response Due
- 9/7/2006
- Archive Date
- 9/22/2006
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Hormonal & Reproductive Epidemiology Branch (HREB) plans to procure on a sole source basis with The University of Southern California (USC), 2250 Alcazar Street, Los Angeles, CA 90033 for DNA extraction, deparaffinization, bisulfite conversion, and MethyLight assays (at 5 loci) on approximately 250 samples. Review of literature and analysis of data from the Polish study has demonstrated breast cancer risk factors and tumor characteristics vary by estrogen receptor (ER) status. Methylation of CpG islands in promoter regions of genes, including the estrogen receptor (ER) gene (ESR1) and the progesterone receptor (PR) gene (PGR), has been associated with loss of expression. However, studies that have assessed ESR1 and PGR gene methylation have been limited by small size, lack of population-defined sampling, and methylation assays that do not interrogate all relevant promoters. Accordingly, the purpose of this procurement is to determine the percentage of breast cancers classified as ER negative that are associated with ESR1 and PGR gene methylation in the population-based Polish Breast Cancer Case-Control Study and to characterize which of the five promoters within the ER gene are methylated. HREB will then estimate the prevalence of DNA methylation at promoter regions of ESR1 and PGR, and examine whether the breast cancer risk associated with reproductive, anthropometry, and hormonal factors differ by tumor subtypes defined by the methylation status of ESR1 and PGR promoter regions. Dr. Peter Laird, an associate professor at University of Southern California School of Medicine, is world renowned for his expertise in the area of DNA methylation and cancer etiology. The USC developed the methodology for the MethyLight assays to be employed in study objectives. MethyLight is an accurate high-throughput methylation assay that utilizes fluorescence-based real-time PCR. The assays differs from other methylation assays in that MethyLight is highly sensitive to low levels of methylation, is quantitative rather than qualitative, and is highly reproducible. Given the large number of samples to be analyzed in this study, the high throughput aspect of the MethyLight assay will produce reliable quantitative measures of methylation at specific loci in a time. The USC previously completed the initial pilot work on a set of samples with frozen tissues. This project will compare the MethyLight results of the paired fixed tissues to those previously assayed frozen tissue samples. Completing this project at the USC will provide the continuity in assay methodology to allow for comparison of paired frozen and fixed tissues. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.5 to use simplified procedures for commercial acquisitions. This is not a solicitation for competitive quotations. However, if any interested party believes it can provide the above service, without introducing new variables into an ongoing research experiments it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. An original and one copy of the capability statements must be received in the contracting office by 1:00 p.m. EDT, on September 7, 2006. Faxed and emailed capability statements are NOT authorized. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to dm170b@nih.gov. It is the vendor's responsibility to call (301) 402-4509 to verify questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award from the NCI contractors must be registered in the Online Representations and Certifications Applications (ORCA). Please refer to http://orca.bpn.gov in order to register. In addition, contractors must be registered in the Central Contractor Registration (CCR) www.ccr.gov. No collect calls will be accepted. NAICS 541380. Size Standard $11M.
- Record
- SN01129638-W 20060901/060830220353 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |